252 related articles for article (PubMed ID: 21508215)
1. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
[TBL] [Abstract][Full Text] [Related]
3. A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors.
Jeon J; Dencker D; Wörtwein G; Woldbye DP; Cui Y; Davis AA; Levey AI; Schütz G; Sager TN; Mørk A; Li C; Deng CX; Fink-Jensen A; Wess J
J Neurosci; 2010 Feb; 30(6):2396-405. PubMed ID: 20147565
[TBL] [Abstract][Full Text] [Related]
4. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
[TBL] [Abstract][Full Text] [Related]
5. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.
Stanhope KJ; Mirza NR; Bickerdike MJ; Bright JL; Harrington NR; Hesselink MB; Kennett GA; Lightowler S; Sheardown MJ; Syed R; Upton RL; Wadsworth G; Weiss SM; Wyatt A
J Pharmacol Exp Ther; 2001 Nov; 299(2):782-92. PubMed ID: 11602695
[TBL] [Abstract][Full Text] [Related]
6. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
[TBL] [Abstract][Full Text] [Related]
7. The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action.
Martino G; Puma C; Yu XH; Gilbert AK; Coupal M; Markoglou N; McIntosh FS; Perkins MN; Laird JMA
Pain; 2011 Dec; 152(12):2852-2860. PubMed ID: 22018972
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.
Byun NE; Grannan M; Bubser M; Barry RL; Thompson A; Rosanelli J; Gowrishankar R; Kelm ND; Damon S; Bridges TM; Melancon BJ; Tarr JC; Brogan JT; Avison MJ; Deutch AY; Wess J; Wood MR; Lindsley CW; Gore JC; Conn PJ; Jones CK
Neuropsychopharmacology; 2014 Jun; 39(7):1578-93. PubMed ID: 24442096
[TBL] [Abstract][Full Text] [Related]
10. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Development of Muscarinic Acetylcholine M
Takai K; Enomoto T
Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
[TBL] [Abstract][Full Text] [Related]
12. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
Shannon HE; Rasmussen K; Bymaster FP; Hart JC; Peters SC; Swedberg MD; Jeppesen L; Sheardown MJ; Sauerberg P; Fink-Jensen A
Schizophr Res; 2000 May; 42(3):249-59. PubMed ID: 10785583
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
[TBL] [Abstract][Full Text] [Related]
14. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
15. Biased Profile of Xanomeline at the Recombinant Human M
McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
[TBL] [Abstract][Full Text] [Related]
16. Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.
Thomsen M; Fulton BS; Caine SB
Psychopharmacology (Berl); 2014 Feb; 231(3):469-79. PubMed ID: 23995301
[TBL] [Abstract][Full Text] [Related]
17. The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain.
Montani C; Canella C; Schwarz AJ; Li J; Gilmour G; Galbusera A; Wafford K; Gutierrez-Barragan D; McCarthy A; Shaw D; Knitowski K; McKinzie D; Gozzi A; Felder C
Neuropsychopharmacology; 2021 May; 46(6):1194-1206. PubMed ID: 33342996
[TBL] [Abstract][Full Text] [Related]
18. Effects of muscarinic M
Stoll K; Hart R; Lindsley CW; Thomsen M
Psychopharmacology (Berl); 2018 Mar; 235(3):815-827. PubMed ID: 29250738
[TBL] [Abstract][Full Text] [Related]
19. Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.
Thomsen M; Wess J; Fulton BS; Fink-Jensen A; Caine SB
Psychopharmacology (Berl); 2010 Feb; 208(3):401-16. PubMed ID: 20013114
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic acetylcholine M
Liu L; Huang Y; Huang Q; Zhao Z; Yu J; Wang L
Neuropharmacology; 2017 May; 117():376-386. PubMed ID: 28257887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
